# Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

> **NCT02273739** · PHASE1,PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 21 (actual)

## Conditions studied

- Solid Tumor
- Glioma
- Angioimmunoblastic T-cell Lymphoma
- Intrahepatic Cholangiocarcinoma
- Chondrosarcoma

## Interventions

- **DRUG:** Enasidenib

## Key facts

- **NCT ID:** NCT02273739
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-08
- **Primary completion:** 2016-06-03
- **Final completion:** 2016-06-03
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2021-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02273739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02273739, "Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT02273739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*